KR102361801B1 - 발렌토닌을 함유하는 경피 치료 시스템 및 약제로서의 그것의 사용 - Google Patents

발렌토닌을 함유하는 경피 치료 시스템 및 약제로서의 그것의 사용 Download PDF

Info

Publication number
KR102361801B1
KR102361801B1 KR1020177024343A KR20177024343A KR102361801B1 KR 102361801 B1 KR102361801 B1 KR 102361801B1 KR 1020177024343 A KR1020177024343 A KR 1020177024343A KR 20177024343 A KR20177024343 A KR 20177024343A KR 102361801 B1 KR102361801 B1 KR 102361801B1
Authority
KR
South Korea
Prior art keywords
vlt
melatonin
valentonin
patch
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177024343A
Other languages
English (en)
Korean (ko)
Other versions
KR20180004100A (ko
Inventor
장-베르나르 푸르틸란
마리안느 푸르틸란
Original Assignee
쏘 요세파 메넨데즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쏘 요세파 메넨데즈 filed Critical 쏘 요세파 메넨데즈
Publication of KR20180004100A publication Critical patent/KR20180004100A/ko
Application granted granted Critical
Publication of KR102361801B1 publication Critical patent/KR102361801B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177024343A 2015-02-04 2016-02-04 발렌토닌을 함유하는 경피 치료 시스템 및 약제로서의 그것의 사용 Expired - Fee Related KR102361801B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305161.0 2015-02-04
EP15305161 2015-02-04
PCT/EP2016/052376 WO2016124688A1 (fr) 2015-02-04 2016-02-04 Systeme therapeutique transdermique contenant de la valentonine et son utilisation comme medicament

Publications (2)

Publication Number Publication Date
KR20180004100A KR20180004100A (ko) 2018-01-10
KR102361801B1 true KR102361801B1 (ko) 2022-02-10

Family

ID=52573642

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177024343A Expired - Fee Related KR102361801B1 (ko) 2015-02-04 2016-02-04 발렌토닌을 함유하는 경피 치료 시스템 및 약제로서의 그것의 사용

Country Status (9)

Country Link
US (1) US10744122B2 (enExample)
EP (1) EP3253378B1 (enExample)
JP (1) JP6785779B2 (enExample)
KR (1) KR102361801B1 (enExample)
CN (1) CN107810003B (enExample)
CA (1) CA2975985A1 (enExample)
ES (1) ES2738633T3 (enExample)
HU (1) HUE045679T2 (enExample)
WO (1) WO2016124688A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101863A1 (fr) * 2006-03-08 2007-09-13 Macef Association therapeutique d'un antagoniste du recepteur 5ht2 et d'activateur du recepteur 5ht2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134493A1 (de) * 1991-10-18 1993-04-22 Teves Gmbh Alfred Blockiergeschuetzte hydraulische bremsanlage
JPH07503232A (ja) * 1991-10-18 1995-04-06 アルザ・コーポレーション メラトニンの制御経皮投与
FR2724384B1 (fr) * 1994-09-14 1999-04-16 Cemaf Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament
AU6595100A (en) * 1999-08-20 2001-03-19 Takeda Chemical Industries Ltd. Percutaneous absorption agents
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
FR2912405A1 (fr) * 2007-02-08 2008-08-15 Fourtillan Snc Derives des imidazo[1',5':1,6]pyrido[3,4-b]indoles et leur utilisation en therapeutique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101863A1 (fr) * 2006-03-08 2007-09-13 Macef Association therapeutique d'un antagoniste du recepteur 5ht2 et d'activateur du recepteur 5ht2

Also Published As

Publication number Publication date
JP2018507850A (ja) 2018-03-22
US20180000796A1 (en) 2018-01-04
HUE045679T2 (hu) 2020-01-28
CN107810003B (zh) 2022-05-03
JP6785779B2 (ja) 2020-11-18
WO2016124688A1 (fr) 2016-08-11
CN107810003A (zh) 2018-03-16
US10744122B2 (en) 2020-08-18
KR20180004100A (ko) 2018-01-10
ES2738633T3 (es) 2020-01-24
EP3253378B1 (fr) 2019-05-08
EP3253378A1 (fr) 2017-12-13
CA2975985A1 (fr) 2016-08-11

Similar Documents

Publication Publication Date Title
Greenblatt et al. Rapid recovery from massive diazepam overdose
Nishioka et al. Stress increases oxytocin release within the hypothalamic paraventricular nucleus
Mathé et al. Non‐NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK‐801) induced hyperlocomotion and dopamine release in the nucleus accumbens
Cheymol et al. Pharmacokinetics of β‐adrenoceptor blockers in obese and normal volunteers
de Souza Silva et al. Dopaminergic and serotonergic activity in neostriatum and nucleus accumbens enhanced by intranasal administration of testosterone
US5756071A (en) Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
Charney et al. α2Adrenergic and Opiate Receptor Blockade: Synergistic Effects on Anxiety in Healthy Subjects
Tao et al. Influence of inhibitory and excitatory inputs on serotonin efflux differs in the dorsal and median raphe nuclei
Mercolini et al. HPLC analysis of the novel antidepressant duloxetine in human plasma after an original solid-phase extraction procedure
Mabrouk et al. CNS penetration of the opioid glycopeptide MMP-2200: A microdialysis study
Hattori et al. Central and systemic oxytocin release: a study of the paraventricular nucleus by in vivo microdialysis
Xie et al. Development and validation of a sensitive LC–MS/MS method for the determination of d-serine in human plasma
SOWERS et al. Evidence for dopaminergic control of circadian variations in thyrotropin secretion
Hutton et al. Controlled study of the antiparkinsonian activity and tolerability of cabergoline
West et al. Intrastriatal infusion of (±)‐S‐nitroso‐N‐acetylpenicillamine releases vesicular dopamine via an ionotropic glutamate receptor‐mediated mechanism: an in vivo microdialysis study in chloral hydrate‐anesthetized rats
Fava et al. Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant
Busettini et al. Effects of mild to moderate sedation on saccadic eye movements
KR102361801B1 (ko) 발렌토닌을 함유하는 경피 치료 시스템 및 약제로서의 그것의 사용
Ishizuka et al. Differential profiles of nitric oxide and norepinephrine releases in the paraventricular nucleus region in response to mild footshock in rats
Coccaro et al. Acute tryptophan depletion attenuates the prolactin response to d-fenfluramine challenge in healthy human subjects
Cecconello et al. DHEA administration modulates stress-induced analgesia in rats
Cenani et al. Pharmacokinetics and pharmacodynamics of intravenous romifidine and propranolol administered alone or in combination for equine sedation
Sato et al. The nitric oxide–guanosine 3′, 5′-cyclic monophosphate pathway regulates dopamine efflux in the medial preoptic area and copulation in male rats
Yu et al. Nicotine self‐administration differentially modulates glutamate and GABA transmission in hypothalamic paraventricular nucleus to enhance the hypothalamic–pituitary–adrenal response to stress
Dingemanse et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48–6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250209

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250209